Apr 19 2019
REDWOOD CITY, Calif. – April 19, 2019 – Auris Health, Inc., a part of Johnson & Johnson Medical Devices Companies, today announced that the Monarch Platform has been recognized with a Gold 2019 Edison Award and a Red Dot: Best of the Best Award. Both award organizations recognize the best products and innovators from around the world. Auris™ creators of the first-of-its-kind robotic endoscopy technology, is being honored for its innovative approach to revolutionizing the diagnosis of lung disease.
The 2019 Edison Awards are an annual competition honoring excellence in new product and service development, marketing, human-centered design and innovation. Award winners represent game-changing products and services, as well as excellence and leadership in innovation around four criteria: concept, value, delivery and impact. Auris’s Monarch Platform received the top prize in its category, the Gold Award.
Auris was also recently selected as a winner for Red Dot’s Best of the Best Award for product design in the medical robotics category. The Red Dot Award is one of the world’s largest design competitions dating back to 1955. The judging panel consists of roughly 40 experts, including designers, design professors and journalists from different fields, who come together for several days in order to assess the products. Designers and companies from 55 countries entered more than 5,500 products in the 2019 competition.
“We are honored to receive recognition from Edison Awards and Red Dot judges for the Monarch Platform, which elevates design to push the boundaries of what is possible in robotic-assisted procedures,” said Josh DeFonzo, Chief Operating Officer at Auris Health. “Monarch’s momentum continues to grow, with many leading doctors and centers adopting the technology. We are excited to be making continued progress in our efforts to help clinicians diagnose lung cancer.”
To design the Monarch Platform, Auris Health enlisted the Fjord connected products team, part of Accenture Interactive. The platform is designed with clinical efficacy and ease-of-use in mind. The robotic system is comprised of a tower, cart, controller, and an instinctive digital user interface that combines traditional endoscopic views with computer-assisted navigation based on 3D models of the patient’s own lung anatomy.
Auris Health’s revolutionary Monarch Platform, the first FDA cleared robotic platform for use in diagnostic and therapeutic bronchoscopic procedures, is designed to allow physicians to diagnose small, hard-to-reach peripheral lung nodules with precision. Lung cancer is the leading cause of cancer deaths worldwide, representing more patient deaths each year than prostate, breast, and colon cancers combined.
About Auris Health, Inc. Auris Health is pioneering the next era of medical intervention by developing platforms that enhance physician capabilities, evolve minimally invasive techniques, and create new categories of care that redefine optimal patient outcomes. The company is committed to transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. Every element of our technology is driven by patient-specific design aimed at maintaining the integrity of the human body. Learn more at www.aurishealth.com.
AURIS and MONARCH are trademarks and/or registered trademarks of Auris Health, Inc. in the United States and in other countries. All other trademarks and product names used herein are the property of their respective owners.
About Johnson & Johnson Medical Devices Companies As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics, vision and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life.
*Comprising the surgery, orthopaedics, vision and interventional businesses within the Johnson & Johnson’s Medical Devices segment
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.